- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Amyotrophic lateral sclerosis
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Riluzole – March 2026
Oral suspension 50 mg per 10 mL, 300 mL
Last updated
11 March 2026